Vedere Bio II is a privately held, emerging biopharmaceutical company leveraging mutation agnostic technology and novel AAV capsids to restore vision in all patients with vision loss due to photoreceptor cell death. Comprised of a diverse team of pioneering scientists, Vedere Bio II is discovering and developing next generation ocular gene therapies to increase the quality of vision restoration and preservation for large, underserved indications. The company is headquartered at LabCentral in Cambridge, MA and is funded by Atlas Venture, Casdin Capital, Mission BioCapital, Octagon Capital, the RD Fund and Samsara BioCapital.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/18/21 | $77,000,000 | Series A |
Atlas Venture Casdin Capital Mission BioCapital Octagon Capital  RD Fund Samsara BioCapital | undisclosed |
